pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Lamivudine Prasco
drug
save

Epivir-HBV

Marketedupdated 3mo ago
by Prasco LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagInfectious Disease2 co-mentions · 2 sources
  • druglamivudine2 co-mentions · 2 sources
  • drugabacavir sulfate1 co-mentions · 1 sources
  • drugTENOFOVIR DISOPROXIL FUMARATE1 co-mentions · 1 sources
  • drug(lamivudine + tenofovir disoproxil fumarate)1 co-mentions · 1 sources
  • drugAbacavir Sulfate Aurobindo1 co-mentions · 1 sources
  • drug(dolutegravir + lamivudine + tenofovir disoproxil fumarate)1 co-mentions · 1 sources
  • company$GSKGSK plc1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Epivir-HBV

  • phase3A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapyactive not recruitingn=307
  • phase3Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primevacompletedn=105
  • phase2A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)recruitingn=150
  • phase3A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatmentnot yet recruitingn=183
  • phase4Efficacy and Safety of Doravirine in the Rapid Initiationnot yet recruitingn=100
  • phase3DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infectionrecruitingn=610
  • phase3Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatmentrecruitingn=150
  • phase4Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)recruitingn=50
more trials →

News(0)

no news has mentioned this drug yet

brand
Lamivudine Prasco
generic
lamivudine
indication
Hepatitis B
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 37m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?